Praxis Precision Medicines
PRAX
103 hedge funds and large institutions have $463M invested in Praxis Precision Medicines in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 10 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 26
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
3% more funds holding
Funds holding: 100 → 103 (+3)
0.14% more ownership
Funds ownership: 6.51% → 6.65% (+0.14%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
46% less capital invested
Capital invested by funds: $863M → $463M (-$399M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$5.07M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$3.13M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$2.41M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$3.82M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.61M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1M |
| 4 |
Citigroup
New York
|
-$690K |
| 5 |
Two Sigma Investments
New York
|
-$519K |
PRAX Hedge Fund Activity: Q1 2022 in Review
103 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q1 2022, worth a combined $463M — down 46% from $863M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PRAX positions and 10 closed out — a net gain of 3 holders — while 39 added to existing stakes and 26 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $8M. The largest seller was Jennison Associates, exiting entirely with an estimated $3.82M sold.
- 103 institutional investors held Praxis Precision Medicines (PRAX) as of Q1 2022, up from 100 in Q4 2021.
- Funds reported $463M of Praxis Precision Medicines stock for Q1 2022, down 46% quarter-over-quarter.
- 13 funds opened new Praxis Precision Medicines positions in Q1 2022 and 10 closed out, a net change of +3 holders.
- The largest Praxis Precision Medicines buyer in Q1 2022 was Eventide Asset Management, an estimated $8M added.
- The largest Praxis Precision Medicines seller in Q1 2022 was Jennison Associates, an estimated $3.82M sold.
Based on aggregated 13F filings for Q1 2022.